AbCellera Biologics Inc

ABCL | $4.06 -2.87% -2.96% 1.3M

(0.0% 1d) (-8.9% 1m) (-43.4% 1y) (0.0% 2d) (0.0% 3d) (-6.3% 7d) (34.39% volume)
Earnings Calendar: 2024-02-20
Market Cap: $ 1,188,695,537
https://www.abcellera.com
Sec Filling | Patents | 206 employees

(CA) AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.

drug discovery education antibody

add to watch list Paper trade email alert is off

Press-releases

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
Published: 2024-04-03 (Crawled : 23:00) - biospace.com/
ABCL | $4.06 -2.87% -2.96% 1.3M

| -3.24% | O: -0.46% H: 3.14% C: 1.86%
first report financial results

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
Published: 2024-03-19 (Crawled : 21:00) - biospace.com/
ABCL | $4.06 -2.87% -2.96% 1.3M

| -8.93% | O: -1.96% H: 0.0% C: 0.0%
conference

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
ABCL | $4.06 -2.87% -2.96% 1.3M

| -12.37% | O: 5.03% H: 0.0% C: 0.0%
BIIB | $195.16 -0.83% -0.85% 870K

Health Technology

| -11.84% | O: 0.03% H: 3.1% C: 3.03%
neurological

AbCellera to Present at Upcoming Investor Conferences in March 2024
Published: 2024-02-23 (Crawled : 08:00) - biospace.com/
ABCL | $4.06 -2.87% -2.96% 1.3M

| -15.81% | O: -1.21% H: 0.0% C: 0.0%

AbCellera Reports Full Year 2023 Business Results
Published: 2024-02-20 (Crawled : 23:00) - biospace.com/
ABCL | $4.06 -2.87% -2.96% 1.3M

| -21.72% | O: 1.12% H: 0.93% C: -1.67%
business year results

AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Published: 2023-12-20 (Crawled : 00:00) - biospace.com/
ABCL | $4.06 -2.87% -2.96% 1.3M

| -26.41% | O: -1.94% H: 0.0% C: 0.0%
conference

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
Published: 2023-11-03 (Crawled : 17:00) - biospace.com/
ABCL | $4.06 -2.87% -2.96% 1.3M

| -0.71% | O: -6.18% H: 0.0% C: 0.0%
t-cell

AbCellera Reports Q3 2023 Business Results
Published: 2023-11-02 (Crawled : 00:00) - biospace.com/
ABCL | $4.06 -2.87% -2.96% 1.3M

| 1.21% | O: 1.94% H: 0.0% C: 0.0%
business results

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Published: 2023-11-01 (Crawled : 20:00) - globenewswire.com
ABCL | $4.06 -2.87% -2.96% 1.3M

| 1.21% | O: 1.94% H: 0.0% C: 0.0%
PRLD | $4.81 -14.57% -17.05% 37K

Health Technology

| 202.69% | O: -6.45% H: 29.31% C: 27.01%
partnership drug antibody therapeutics

AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
Published: 2023-10-31 (Crawled : 23:00) - biospace.com/
ABCL | $4.06 -2.87% -2.96% 1.3M

| 3.47% | O: 0.87% H: 0.0% C: 0.0%
conference

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001703057-24-000008	4	2024-01-16	2024-01-14	Buy	A	770416	3913105
0001703057-24-000006	4	2024-01-16	2024-01-14	Buy	A	616333	3274714